Interleukin Genetics Appoints Eliot M. Lurier Chief Financi... (ncluding Chief Financial Officer ofAdmet...)

Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer

Date:4/30/2008

ncluding Chief Financial Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer and Vice President of Finance of Ascent Pediatrics, Inc., a publicly traded pharmaceutical company.

Earlier in his career, Mr. Lurier was Senior Accountant at Coopers and Lybrand. He earned a B.S. in Accounting from Syracuse University and is a Certified Public Accountant in Massachusetts.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, gi
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
2. Interleukin Genetics Retains Top Life Science Communications Firms
3. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
6. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
7. Interleukin Genetics Announces Management and Board Appointments
8. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
9. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
10. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
11. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference

Post Your Comments:

Interleukin Genetics Appoints Eliot M. Lurier Chief Financi...(ncluding Chief Financial Officer ofAdmet...)